Novo Nordisk's reimbursement appeal goes unheard, Sanofi insulin deemed equivalent

The Danish Medicines Agency's Reimbursement Committee has decided to ignore Novo Nordisk's pleas to leave the company's general reimbursement scheme untouched. Instead, it recommends other fast-acting insulins for new patients.

A trip to the pharmacy for users of Novo Nordisk's Fiasp could become more expense going forward. The Danish Medicines Agency's Reimbursement Committee has recommended a adjusting the fast-acting insulin's reimbursement scheme for the worse.

The Danish Medicines Agency has received the Reimbursement Committee's final recommendation for a revision pertaining to the reimbursement scheme for insulin products – and it doesn't bode well for Novo Nordisk.

Attempts to convince the committee to change their minds have fallen short. At the beginning of November, the Danish pharmaceutical firm objected to the change to reimbursements, which would see Novo Nordisk's fast-acting insulin Fiasp receive conditional reimbursement as opposed to a general reimbursement.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs